skip to main content
DOE Patents title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Anticancer therapy

Abstract

A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.

Inventors:
Issue Date:
Research Org.:
STC.UNM, Albuquerque, NM (United States)
Sponsoring Org.:
USDOE
OSTI Identifier:
1349739
Patent Number(s):
9610371
Application Number:
14/669,313
Assignee:
STC.UNM
Patent Classifications (CPCs):
A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
DOE Contract Number:  
FG01-001NE23554
Resource Type:
Patent
Resource Relation:
Patent File Date: 2015 Mar 26
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; 59 BASIC BIOLOGICAL SCIENCES

Citation Formats

Norenberg, Jeffrey P. Anticancer therapy. United States: N. p., 2017. Web.
Norenberg, Jeffrey P. Anticancer therapy. United States.
Norenberg, Jeffrey P. Tue . "Anticancer therapy". United States. https://www.osti.gov/servlets/purl/1349739.
@article{osti_1349739,
title = {Anticancer therapy},
author = {Norenberg, Jeffrey P.},
abstractNote = {A subject afflicted with a cancer or precancerous condition is treated by administering an agent that increases expression of somatostatin receptors, and a cytotoxic recognition ligand. In an alternative embodiment, somatostatin analogs, which are radiolabeled are used to treat cancer or precancerous conditions.},
doi = {},
journal = {},
number = ,
volume = ,
place = {United States},
year = {2017},
month = {4}
}

Patent:

Save / Share:

Works referenced in this record:

Nephrotoxicity in Mice After Repeated Imaging Using 111In-Labeled Peptides
journal, May 2010


Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
journal, November 2009


Tumor Imaging and Therapy Using Radiolabeled Somatostatin Analogues
journal, July 2009


Long-term toxicity of [177Lu-DOTA0,Tyr3]octreotate in rats
journal, September 2006


Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings
journal, April 2002


Phase I study of peptide receptor radionuclide therapy with [111In-DTPA0]octreotide: The rotterdam experience
journal, April 2002


Experimental facts supporting a red marrow uptake due to radiometal transchelation in 90Y-DOTATOC therapy and relationship to the decrease of platelet counts
journal, February 2011


Phase I Trial of 90Y-DOTATOC Therapy in Children and Young Adults with Refractory Solid Tumors That Express Somatostatin Receptors
journal, September 2010


Lymphocytic Toxicity in Patients After Peptide-Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC
journal, December 2009


Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors
journal, April 2008


Therapy using labelled somatostatin analogues: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
journal, January 2008


Treatment with 90Y- and 177Lu-DOTATOC in patients with metastatic neuroendocrine tumors
journal, December 2006


Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium-labelled somatostatin analogue: a pilot trial
journal, September 2004


Receptor Radionuclide Therapy with 90Y-DOTATOC in Patients with Medullary Thyroid Carcinomas
journal, February 2004


Assessment of Hepatic Toxicity from Treatment with 90Y-SMT 487 (OctreoTher™) in Patients with Diffuse Somatostatin Receptor Positive Liver Metastases
journal, August 2003


90Y-DOTA-D-Phe1-Try3- octreotide in therapy of neuroendocrine malignancies
journal, January 2002


Yttrium-90 DOTATOC: first clinical results
journal, October 1999